1. Pink Sheet

Podcast: Accelerating Antibiotics – Kevin Outterson And Joe Larsen Explain CARB-X

 
• By Laura Helbling

Podcast with CARB-X Executive Director Kevin Outterson and BARDA Acting Deputy Director Joe Larsen describes the work of the accelerator, which just announced the first eleven projects in its portfolio.

Antibiotic resistant bacteria closeup biofilm

The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, announced the first eleven projects in its Powered by CARB-X portfolio March 30. The initial portfolio includes three projects on new classes of antibiotics and four projects on non-traditional products, such as immunotherapy or antibody-drug candidates.

We talked to Executive Director Kevin Outterson about narrowing down applicants from the wide interest and upcoming additions to the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

Indegene Exec On DTP Distribution As A ‘Tactical Solution’, Feasibility Of MFN Model

 
• By Anju Ghangurde

Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US, including potentially introducing new intermediaries into the system. Questions on MFN's feasibility and why it may be “catastrophic” to biopharma were also part of the discussion

Best Laid Plans: A Chronology Of Post-Pandemic COVID-19 Vaccines

 
• By Bridget Silverman

Quick responses to late-breaking changes to US FDA COVID-19 vaccine policy kept Novavax's Nuvaxovid and Moderna's mNexspike close to expected approval timelines despite revised indications and new post-marketing trial commitments.

Last Minute Course Shifts, Focus On Unknowns: What Sponsors Should Learn From Prasad’s Interventions

 
• By Sarah Karlin-Smith

The once and current CBER director’s justification for his COVID-19 decision stands as a warning of the uncertainty sponsors, particularly those in the vaccine space, may now face at FDA.